RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug

Blood

Volumn 125, Issue 24, 2015, Pages 3760-3768

  Wermke, Martin ^a,b   Camgoz, Aylin ^b   Paszkowski Rogacz, Maciej ^b   Thieme, Sebastian ^a   Von Bonin, Malte ^a,c   Dahl, Andreas ^b   Platzbecker, Uwe ^a   Theis, Mirko ^b   Ehninger, Gerhard ^a   Brenner, Sebastian ^a   Bornhäuser, Martin ^a   Buchholz, Frank ^b,c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; FASUDIL; LENTIVIRUS VECTOR; SHORT HAIRPIN RNA; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; RHO KINASE; ROCK1 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BNIPL1 GENE; CANCER STEM CELL; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GENE; GENE IDENTIFICATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LOSS OF FUNCTION MUTATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RNA INTERFERENCE; ROCK1 GENE; RPS13 GENE; SNX27 GENE; STK3 GENE; WDHD1 GENE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; LEUKEMIA, MYELOID, ACUTE; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR CELL CULTURE;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; RNA INTERFERENCE; TUMOR CELLS, CULTURED;

EID: 84931287944     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-590646     Document Type: Article

References (49)

1. Schiller GJ. High-risk acute myelogenous leukemia: treatment today ... and tomorrow. Hematology Am Soc Hematol Educ Program. 2013;2013(1):201-208.
2. Hochhaus A, O'Brien SG, Guilhot F, et al IRIS Investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6): 1054-1061.
3. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249-1259.
4. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22): 2091-2101.
5. Büchner T, Schlenk RF, Schaich M, et al. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm-combined prospective analysis by the German AML Intergroup. J Clin Oncol. 2012; 30(29):3604-3610.
6. Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol. 2013;31(25):3110-3118.
7. Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013; 31(29):3681-3687.
8. Lancet JE. New agents: great expectations not realized. Best Pract Res Clin Haematol. 2013; 26(3):269-274.
9. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.
10. Bernards R, Brummelkamp TR, Beijersbergen RL. shRNA libraries and their use in cancer genetics. Nat Methods. 2006;3(9):701-706.
11. Hannon GJ. RNA interference. Nature. 2002; 418(6894):244-251.
12. Root DE, Hacohen N, Hahn WC, Lander ES, Sabatini DM. Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods. 2006;3(9):715-719.
13. Porter CC, Kim J, Fosmire S, et al. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia. 2012;26(6): 1266-1276.
14. Tibes R, Bogenberger JM, Chaudhuri L, et al. RNAi screening of the kinome with cytarabine in leukemias. Blood. 2012;119(12):2863-2872.
15. Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370): 524-528.
16. Moffat J, Grueneberg DA, Yang X, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 2006;124(6):1283-1298.
17. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25.
18. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-792.
19. Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009;113(26): 6541-6548.
20. Stirewalt DL, Meshinchi S, Kopecky KJ, et al. Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer. 2008;47(1):8-20.
21. Fang B. Development of synthetic lethality anticancer therapeutics. J Med Chem. 2014; 57(19):7859-7873.
22. Rath N, Olson MF. Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. EMBO Rep. 2012;13(10): 900-908.
23. Mali RS, Ramdas B, Ma P, et al. Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Cancer Cell. 2011;20(3):357-369.
24. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol. 2007;50(1): 17-24.
25. Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E; Fasudil Ischemic Stroke Study Group. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci. 2005;238(1-2):31-39.
26. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408(3):297-315.
27. Lai WH, Ho JC, Lee YK, et al. ROCK inhibition facilitates the generation of human-induced pluripotent stem cells in a defined, feeder-, and serum-free system. Cell Reprogram. 2010;12(6): 641-653.
28. Castro DJ, Maurer J, Hebbard L, Oshima RG. ROCK1 inhibition promotes the self-renewal of a novel mouse mammary cancer stem cell. Stem Cells. 2013;31(1):12-22.
29. Sutherland HJ, Lansdorp PM, Henkelman DH, Eaves AC, Eaves CJ. Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proc Natl Acad Sci USA. 1990; 87(9):3584-3588.
30. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994; 367(6464):645-648.
31. von Bonin M, Wermke M, Cosgun KN, et al. In vivo expansion of co-transplanted T cells impacts on tumor re-initiating activity of human acute myeloid leukemia in NSG mice. PLoS ONE. 2013; 8(4):e60680.
32. Shi J, Wei L. Rho kinase in the regulation of cell death and survival. Arch Immunol Ther Exp (Warsz). 2007;55(2):61-75.
33. Bishop AL, Hall A. Rho GTPases and their effector proteins. Biochem J. 2000;348(Pt 2):241-255.
34. Croft DR, Coleman ML, Li S, et al. Actin-myosinbased contraction is responsible for apoptotic nuclear disintegration. J Cell Biol. 2005;168(2): 245-255.
35. Sebbagh M, Renvoizé C, Hamelin J, Riché N, Bertoglio J, Bréard J. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol. 2001;3(4):346-352.
36. Liu L, Li G, Li Q, et al. Triptolide induces apoptosis in human leukemia cells through caspase-3- mediated ROCK1 activation and MLC phosphorylation. Cell Death Dis. 2013;4(12): e941.
37. Tönges L, Frank T, Tatenhorst L, et al. Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease. Brain. 2012; 135(Pt 11):3355-3370.
38. Yang S, Kim HM. ROCK inhibition activates MCF-7 cells. PLoS ONE. 2014;9(2):e88489.
39. Zhang C, Zhang S, Zhang Z, He J, Xu Y, Liu S. ROCK has a crucial role in regulating prostate tumor growth through interaction with c-Myc. Oncogene. 2014;33(49):5582-5591.
40. Ying H, Biroc SL, Li WW, et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther. 2006;5(9):2158-2164.
41. Delgado MD, León J. Myc roles in hematopoiesis and leukemia. Genes Cancer. 2010;1(6):605-616.
42. Burthem J, Rees-Unwin K, Mottram R, et al. The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(1) CML progenitor cells. Leukemia. 2007;21(8):1708-1714.
43. Shimokawa H, Hiramori K, Iinuma H, et al. Antianginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol. 2002;40(5): 751-761.
44. Suzuki Y, Shibuya M, Satoh S, Sugiyama H, Seto M, Takakura K. Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. Neurol Med Chir (Tokyo). 2008;48(6):241-247, discussion 247-248.
45. Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010;329(5997):1345-1348.
46. Fellmann C, Hoffmann T, Sridhar V, et al. An optimized microRNA backbone for effective single-copy RNAi. Cell Reports. 2013;5(6): 1704-1713.
47. Frecha C, Costa C, Nègre D, et al. A novel lentiviral vector targets gene transfer into human hematopoietic stem cells in marrow from patients with bone marrow failure syndrome and in vivo in humanized mice. Blood. 2012;119(5): 1139-1150.
48. Leuci V, Mesiano G, Gammaitoni L, et al. Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(1) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors. JBiotechnol.2011;156(3):218-226.
49. Zhou J, Rossi JJ. Cell-type-specific, aptamerfunctionalized agents for targeted disease therapy. Mol Ther Nucleic Acids. 2014;3:e169.